Shoichiro Kajinami, Author at Kluwer Patent Blog

Japan: Sawai’s Generic Drug is approved by the MHLW amid patent litigation with Bristol-Myers Squibb, but the Court orders preliminary injunction against Sawai soon after

Mami Hino, Naho Ebata, Shoichiro Kajinami (Abe, Ikubo & Katayama)/January 9, 2024January 9, 2024

On November 28, 2023, the Tokyo District Court issued a preliminary injunction order against Sawai Pharmaceutical Co., Ltd. (“Sawai”) to suspend the manufacture and sale of Sawai’s pharmaceutical product (“Sawai’s Product”) developed and sold as a generic drug of Bristol-Myers Squibb (“BMS”)’s cancer drug “Sprycel®” (Case No. 2023 (Yo) 30214; AIK represented BMS in this…

Case Law, Japan

Japan IP High Court’s first-ever decision allowing patent enforcement against infringing acts partially committed outside of Japan

Mami Hino, Naho Ebata, Shoichiro Kajinami (Abe, Ikubo & Katayama)/December 12, 2022December 12, 2022

On July 20, 2022, the Japan Intellectual Property High Court (“IP High Court”) rendered the first-ever decision allowing enforcement of Japanese patent rights against infringing acts partially committed outside of Japan (Case No. 2018 (Ne) 10077). The plaintiff Dwango Co., Ltd. sued co-defendants FC2, Inc. (U.S. company) and Homepage System, Inc. (Japanese company), alleging that…